Lancet Respiratory Medicine

Papers
(The TQCC of Lancet Respiratory Medicine is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-06-01 to 2024-06-01.)
ArticleCitations
Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 20171070
Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans918
COVID-19 cytokine storm: the interplay between inflammation and coagulation915
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy751
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes642
Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study590
COVID-19 and the impact of social determinants of health481
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study480
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial475
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study452
Management of acute kidney injury in patients with COVID-19434
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis433
Particle sizes of infectious aerosols: implications for infection control421
SARS-CoV-2 viral load predicts COVID-19 mortality413
Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures399
Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study393
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study388
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial373
Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study363
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity362
Pulmonary fibrosis secondary to COVID-19: a call to arms?357
Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities354
COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?350
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial334
Human recombinant soluble ACE2 in severe COVID-19330
Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study330
Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19320
Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study318
NICE guideline on long COVID314
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society306
Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study296
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers279
New variant of SARS-CoV-2 in UK causes surge of COVID-19278
Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission278
Tracheostomy in the COVID-19 era: global and multidisciplinary guidance277
Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data277
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial274
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials274
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial270
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicent266
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial265
False-positive COVID-19 results: hidden problems and costs255
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study245
COVID-19: a heavy toll on health-care workers239
Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial234
Omicron variant and booster COVID-19 vaccines221
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial207
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study205
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities204
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform203
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial203
Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses193
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial189
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial185
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial181
Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study180
Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study176
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, contr172
Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study170
Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries168
Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study168
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an ope164
Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?157
Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study153
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controll148
SARS-CoV-2 evolution and vaccines: cause for concern?147
Chronic respiratory diseases: a global view144
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study144
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial142
Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies141
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial139
Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment139
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial136
Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study135
Immunomodulation in COVID-19134
Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial129
Tobacco smoking and COVID-19 infection127
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study127
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial127
Interleukin-6: obstacles to targeting a complex cytokine in critical illness126
Subphenotypes in critical care: translation into clinical practice124
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation122
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial121
Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19119
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-labe118
COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study116
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Character114
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study113
Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care113
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?112
The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions108
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study107
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial107
Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study107
Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study106
Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene–environment interactions across the lifespan106
Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database106
COVID-19 transmission—up in the air106
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (AND105
Immunotherapies for COVID-19: lessons learned from sepsis105
A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study105
Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities105
Respiratory health in athletes: facing the COVID-19 challenge104
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial103
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled pha102
Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: an observational study using administrative data102
The Russian vaccine for COVID-19102
Implications of the second wave of COVID-19 in India102
Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient101
Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis100
Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study97
The genetics of asthma and the promise of genomics-guided drug target discovery97
Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a random97
Major differences in ICU admissions during the first and second COVID-19 wave in Germany96
Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study96
Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 201995
Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties95
Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study94
Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus93
GOLD COPD report: 2023 update93
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial90
Advancing precision medicine for acute respiratory distress syndrome90
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial90
When to consider lung transplantation for COVID-1990
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial90
COVID-19 interstitial pneumonia: monitoring the clinical course in survivors89
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi88
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December,87
Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base86
The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease86
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and84
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,84
Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controll84
Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort84
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context84
Saliva as a gold-standard sample for SARS-CoV-2 detection83
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study83
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial82
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled82
The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?82
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial82
Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial82
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study82
Advances in understanding and reducing the burden of severe asthma in children81
Lifting of COVID-19 restrictions in the UK and the Delta variant81
Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study80
Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study80
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase80
The global prevalence and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database analysis79
Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study78
Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management77
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations77
Allocating scarce intensive care resources during the COVID-19 pandemic: practical challenges to theoretical frameworks77
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials77
Corticosteroids for COVID-19: the search for an optimum duration of therapy75
Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis75
The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study74
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-74
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK73
COVID-19 among people experiencing homelessness in England: a modelling study73
Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts72
Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial72
Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study71
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, doubl71
The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study71
Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts71
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial70
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial70
Variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational study69
Long COVID: aiming for a consensus69
Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials69
Challenges in lung cancer therapy during the COVID-19 pandemic68
Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis67
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis67
COVID-19 in Nigeria: a disease of hunger67
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis67
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial67
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study66
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study66
Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study65
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study65
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities65
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study65
Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials64
Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis64
SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors63
Use of non-invasive ventilation for patients with COVID-19: a cause for concern?63
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub63
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised63
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial62
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial62
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study62
National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study62
Use of facemasks during the COVID-19 pandemic61
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomise61
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial61
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 tri60
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial60
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial59
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO59
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers58
Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial57
COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion57
Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine56
Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis55
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label55
Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study55
Dynamic zero COVID policy in the fight against COVID55
Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making?55
COVID-19 hospital admissions: Brazil's first and second waves compared55
Delayed-onset myocarditis following COVID-1954
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study54
Immunomodulation by macrolides: therapeutic potential for critical care54
Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, ran53
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial52
Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomi52
A new paradigm is needed to explain long COVID51
Imaging research in fibrotic lung disease; applying deep learning to unsolved problems51
Lung function testing in the COVID-19 endemic51
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial50
Extracorporeal membrane oxygenation for COVID-19 during first and second waves50
Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?50
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial49
Risk of COVID-19 hospital admission among children aged 5–17 years with asthma in Scotland: a national incident cohort study49
Could a good night's sleep improve COVID-19 vaccine efficacy?48
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study48
Aerosol generating procedures: are they of relevance for transmission of SARS-CoV-2?48
A 5-point strategy for improved connection with relatives of critically ill patients with COVID-1948
Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3)47
Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder47
Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)47
Effect of early mobilisation on long-term cognitive impairment in critical illness in the USA: a randomised controlled trial47
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co46
Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study46
Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study45
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study45
Repurposing drugs for treatment of COVID-1945
GOLD report: 2022 update44
Trajectories of asthma and allergies from 7 years to 53 years and associations with lung function and extrapulmonary comorbidity profiles: a prospective cohort study44
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study44
Asthma in children during the COVID-19 pandemic: lessons from lockdown and future directions for management44
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials43
The role of antiviral treatment in the COVID-19 pandemic43
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial43
Assessing the importance of interleukin-6 in COVID-1943
Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study43
Association between very to moderate preterm births, lung function deficits, and COPD at age 53 years: analysis of a prospective cohort study43
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study42
α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action42
The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study42
0.52128601074219